Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. Financial Results: Neuland
Neuland Laboratories Limited
-(NEULANDLAB)
XNSE:NEULANDLAB, XBOM:NEULANDLAB
Neuland Laboratories Limited Q4 FY24 Earnings Conference Call Insights
Key highlights from Neuland Laboratories Limited (NEULANDLAB) Q4 FY24 Earnings Concall Financial Performance Total income for FY '24 was INR 1,511 crores,
Neuland Laboratories Ltd Q3FY24; 161% rise in Profits
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. Financial Results: Neuland
Neuland Laboratories Ltd Q1FY24; 520% rise in Profits
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. Financial Results: Neuland
Neuland Laboratories Limited (NEULANDLAB) Q4 FY23 Earnings Concall Transcript
Neuland Laboratories Limited (NSE:NEULANDLAB) Q4 FY23 Earnings Concall dated May. 11, 2023. Corporate Participants: Ravi Udeshi -- Investor Relations Abhijit Majumdar. -- Chief Financial Officer Saharsh
Neuland Laboratories Q4FY23 Earnings Story
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. Financial Results: Neuland
Neuland Laboratories Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Neuland Laboratories Limited (NEULANDLAB) Q3 FY23 Earnings Concall Management Update: [00:05:35] NEULANDLAB said its raw material prices are becoming
Neuland Laboratories Limited (NEULANDLAB) Q3 FY23 Earnings Concall Transcript
Neuland Laboratories Limited (NSE:NEULANDLAB) Q3 FY23 Earnings Concall dated Feb. 14, 2023. Corporate Participants: Abhijit Majumdar -- Chief Financial Officer Saharsh Davuluri -- Vice Chairman and
Neuland Laboratories Limited Q4 FY22 Earnings Conference Call Insights
https://youtu.be/SoKfArytP_s Key highlights from Neuland Laboratories Limited (NEULANDLAB) Q4 FY22 Earnings Concall Management Update: NEULANDLAB said its capex plan is on track